Its official: FDA’s drug center has already approved more new molecules in 2008 than it did in 2007—despite missed user fee deadlines, a regulatory posture defined as "Safety First" and a general perception that it’s never been harder to get drugs to market. Maybe there is an upside to the new regulatory system after all.
We all know the story: Missed user fee deadlines. Multiple cycle reviews. A regulatory posture defined by the phrase "Safety...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?